Therefore, to build upon these initial finding, our study aims to provide a comprehensive analysis of the immunological functions and therapeutic vulnerabilities associated with PLOD gene family in ccRCC. This evidence concerns the gene PLOD1 and nonpapillary renal cell carcinoma.